EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real‐World Implementation and Clinical Outcomes

Saskia Hussung iD, Mia Roth, Dilara Akhoundova, Clelia Pistoni iD, Judith Konrat iD, Franca Lisy, Tabea Ibach, Tomas Brezina, Markus Rechsteiner, Daniela Lenggenhager iD, Martin Zoche, Holger Moch iD und 2 weitere

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72461 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 03.11.2026. Verfasst von Saskia Hussung und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Genomics, Gene Expression Profiling, Biomarkers, Tumor. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Walter-und-Gertrud-Siegenthaler Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biliary Tract Cancers (BTCs) are difficult‐to‐treat malignancies with limited therapeutic options and dismal prognosis. Upfront comprehensive genomic profiling (CGP) is recommended for advanced BTC to identify actionable alterations, but its real‐world implementation remains underexplored.

Methods

In 2019, we implemented upfront CGP for advanced BTC at our institution. Molecular profiling results were reviewed within our institutional molecular tumor board when clinically applicable. Patients were followed throughout their disease course.

Results

A total of 80 patients with locally unresectable ( n = 14) or metastatic ( n = 66) BTC underwent CGP. Testing was performed on cytology material (6/80), tumor biopsies (38/80), or surgical specimens (36/80). In 59/80 cases (73.8%) testing was carried out prior to the beginning of palliative first‐line treatment. In 42/80 (52.5%) cases, at least one clinically actionable genomic alteration was identified. The most frequent actionable alterations involved IDH1 (13.8%), FGFR2 (8.8%), ERBB2 (HER2) (5.0%), KRAS G12C (2.5%), and BRAF (1.3%). Alterations in DNA damage response genes were detected in 11/80 tumors, and 3/80 were dMMR/MSI‐H. FGFR2 and IDH1 mutations were detected in ICC only, while HER2 alterations were more commonly detected in ECC and GBC. 11/42 patients with a clinically actionable alteration received targeted treatment during the disease course (1 first‐line, 10 later lines). Among patients with an evaluable preceding systemic treatment line, treatment duration was longer with molecularly matched treatment than with the immediately preceding treatment line ( p = 0.0391). 2/14 patients with initially unresectable BTC achieved secondary resectability during molecularly matched treatment.

Conclusion

Upfront CGP is feasible in routine clinical practice and identifies clinically actionable alterations in a substantial proportion of patients with advanced BTC. However, only a subset received molecularly matched treatment, highlighting a gap between molecular actionability and treatment implementation. Timely access to matched therapies remains critical to the clinical utility of precision oncology in BTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsGenomicsGene Expression ProfilingBiomarkers, TumorHumansFemaleMaleAgedMiddle AgedMutationAged, 80 and overAdultPrognosisTreatment Outcome

Stichwörter der Autor:innen

biliary tract cancercomprehensive genomic profilingpersonalized treatmentprecision oncology

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
  • University of Zurich, Zurich, Switzerland.
  • Department of Medical Oncology, Inselspital, University Hospital of Bern, Bern, Switzerland.
  • Department for BioMedical Research, University of Bern, Bern, Switzerland.
  • Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Institute of Molecular Cancer Research (IMCR), University of Zurich, Zurich, Switzerland.

ORCID-Profile: Saskia Hussung, Clelia Pistoni, Judith Konrat, Daniela Lenggenhager, Holger Moch, Achim Weber

Förderung

  • Walter-und-Gertrud-Siegenthaler Foundation

Zitieren

APA

Hussung, S., Roth, M., Akhoundova, D., Pistoni, C., Konrat, J., Lisy, F., Ibach, T., Brezina, T., Rechsteiner, M., Lenggenhager, D., Zoche, M., Moch, H., Weber, A., & Fritsch, R. (2026). Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real‐World Implementation and Clinical Outcomes. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72461

Vancouver

Hussung S, Roth M, Akhoundova D, Pistoni C, Konrat J, Lisy F, et al. Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real‐World Implementation and Clinical Outcomes. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72461

BibTeX
@article{Hussung2026,
  author = {Hussung, Saskia and Roth, Mia and Akhoundova, Dilara and Pistoni, Clelia and Konrat, Judith and Lisy, Franca and Ibach, Tabea and Brezina, Tomas and Rechsteiner, Markus and Lenggenhager, Daniela and Zoche, Martin and Moch, Holger and Weber, Achim and Fritsch, Ralph},
  title = {Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real‐World Implementation and Clinical Outcomes},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.72461}
}
Kostenlos starten →